| RS2143878968 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879304 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879509 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879547 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879651 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879667 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143879675 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143880536 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143880646 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143882034 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143882664 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143882997 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143883054 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143883097 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143883327 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143883845 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143884018 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143885612 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143885916 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886056 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886403 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143886422 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886507 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886751 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886864 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143886904 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143887003 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143887054 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143887087 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143887823 |
LOXHD1
|
Health Risk |
Pathogenic |
— |
| RS2143888280 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143891559 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143892028 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143892473 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143892615 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143892654 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143893153 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143895928 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143896492 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143897458 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143903171 |
DNAI2
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS2143904159 |
DNAI2
|
Health Risk |
Likely pathogenic |
Primary ciliary dyskinesia 9, Primary ciliary dyskinesia 9 |
| RS2143904721 |
UNC13D
|
Health Risk |
Pathogenic |
Familial hemophagocytic lymphohistiocytosis 3, Familial hemophagocytic lymphohistiocytosis 3 |
| RS2143913299 |
PIEZO2
|
Health Risk |
Pathogenic |
Arthrogryposis- oculomotor limitation-electroretinal anomalies syndrome, Arthrogryposis- oculomotor limitation-electroretinal anomalies syndrome |
| RS2143913707 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143913948 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143914353 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143914685 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143914721 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143914781 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143914954 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143914991 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143915068 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143915236 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143916424 |
LOXHD1
|
Health Risk |
Pathogenic |
— |
| RS2143918072 |
LOXHD1
|
Health Risk |
Pathogenic |
Autosomal recessive nonsyndromic hearing loss 77, Autosomal recessive nonsyndromic hearing loss 77 |
| RS2143919227 |
LOXHD1
|
Health Risk |
Pathogenic |
— |
| RS2143919451 |
GAA
|
Health Risk |
Likely pathogenic |
— |
| RS2143920189 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143921132 |
LOXHD1
|
Health Risk |
Likely pathogenic |
— |
| RS2143924649 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143924790 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143925134 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143925402 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143926009 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143929613 |
RAD51C
|
Health Risk |
Likely pathogenic |
Breast-ovarian cancer, familial |
| RS2143930383 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143930413 |
RAD51C
|
Health Risk |
Pathogenic |
Breast-ovarian cancer, familial |
| RS2143930800 |
GAA
|
Health Risk |
Pathogenic |
Glycogen storage disease, type II |
| RS2143930978 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143931061 |
GAA
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease, type II |
| RS2143932427 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia complementation group O, Hereditary cancer-predisposing syndrome |
| RS2143934702 |
GAA
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type II |
| RS2143936992 |
BCKDK
|
Health Risk |
Pathogenic |
Branched-chain keto acid dehydrogenase kinase deficiency, Branched-chain keto acid dehydrogenase kinase deficiency |
| RS2143940594 |
DNAI2
|
Health Risk |
Likely pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS2143957245 |
LOXHD1
|
Health Risk |
Pathogenic |
— |
| RS2143958483 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143958767 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143958833 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143959211 |
NF1
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2143959220 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143959373 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143959428 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143959602 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143959812 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143959905 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960130 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960248 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960301 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960519 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960631 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960778 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143960866 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143961181 |
RAD51C
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143961266 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Breast carcinoma, Fanconi anemia complementation group O |
| RS2143961536 |
RAD51C
|
Health Risk |
Likely pathogenic |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group O |
| RS2143961567 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |
| RS2143962519 |
RAD51C
|
Health Risk |
Conflicting classifications of pathogenicity |
Breast-ovarian cancer, familial |
| RS2143962532 |
FAM20A
|
Health Risk |
Likely pathogenic |
— |
| RS2143963184 |
RAD51C
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group O, Breast-ovarian cancer |